Welcome to our dedicated page for Palisade Bio SEC filings (Ticker: PALI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Palisade Bio’s regulatory paperwork is not for the faint-hearted. The company’s 10-K packs dense discussions about cash runway, clinical-trial risk and intestinal-barrier science, while each 8-K can shift sentiment overnight. If you’ve ever wondered “where can I find Palisade Bio’s quarterly earnings report 10-Q filing?” or tried to follow a sudden share offer buried in an S-1, you know the challenge. Stock Titan’s AI-powered analysis puts those worries to rest.
Our AI summaries deliver Palisade Bio SEC filings explained simply. See R&D spend trends in the latest Palisade Bio quarterly earnings report 10-Q filing, catch every Palisade Bio 8-K material events explained, and monitor Palisade Bio insider trading Form 4 transactions in real time. Whether you need the Palisade Bio annual report 10-K simplified or Palisade Bio proxy statement executive compensation details, one click reveals plain-English insights, key tables and cross-document links.
Because pipeline progress drives valuation, investors track dilution risk, milestone payments and executive incentives. Our dashboard alerts you to Palisade Bio Form 4 insider transactions real-time, flags new at-the-market offerings, and highlights how fresh trial data could affect funding needs. Stop opening dozens of PDFs—understanding Palisade Bio SEC documents with AI means you get answers faster: Is management buying or selling? How long does cash last? What happens if the Phase 2 readout slips? Stock Titan delivers the Palisade Bio earnings report filing analysis you need—faster than the market.
Palisade Bio's preliminary proxy requests shareholder votes on three principal proposals: elect three directors for terms ending at the 2026 annual meeting, ratify Baker Tilly US, LLP as the independent registered public accounting firm for fiscal 2025, and approve an amendment authorizing the Board to implement a reverse stock split at a ratio between 1-for-5 and 1-for-50 to be effected on or before December 31, 2025. The document explains voting methods for an online-only annual meeting and describes factors the Board will consider in setting a split ratio, including trading price, liquidity, authorized shares and potential impacts on market capitalization and Nasdaq continued listing. Proxy voting procedures, potential odd-lot effects post-split, executive compensation disclosures and recent financing transactions with institutional investors (including Armistice Capital) and exercise-price adjustments for previously issued warrants are included.
Palisade Bio director Donald Allen received a grant of 64,400 phantom units on 09/04/2025. Each phantom unit represents the economic equivalent of one share of Palisade Bio common stock. The award vests in three equal annual installments beginning August 5, 2026, provided the reporting person remains in continuous service through each vesting date. Vested phantom units will be settled solely in cash based on the fair market value of an equal number of shares upon termination of service, a liquidity change in control, or the seventh anniversary of the grant. The reporting person’s ownership after the grant is 64,400 common stock equivalents, held directly.
Palisaade Bio insider grant: The filing shows that John David Finley, a director and officer (listed as CEO, CFO), was granted 323,400 Phantom Units on 09/04/2025. Each Phantom Unit equals the economic value of one share of common stock and the award vests in 12 equal quarterly installments beginning November 5, 2025, subject to the reporting persons continuous service through each vesting date. Vested Phantom Units will be settled solely in cash based on the fair market value of an equal number of shares upon the earliest of termination by the issuer without cause, a liquidity change in control, or the 7th anniversary of the grant date, per the issuers Phantom Unit Plan. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Wei Binxian, a director of Palisade Bio, Inc. (PALI), was granted 18,800 phantom units on 09/04/2025. Each phantom unit mirrors the economic value of one share of common stock and the grant is recorded as 18,800 units with a $0 exercise price. The phantom units vest in three equal annual installments beginning August 5, 2026, subject to the reporting persons continuous service through each vesting date. Vested units will be settled solely in cash based on the fair market value of an equal number of shares upon termination of service, a defined change in control, or the seventh anniversary of the grant date. The Form 4 was signed by an attorney-in-fact on 09/05/2025.
Palisade Bio insider grant: Jones Mitchell Lawrence, listed as an officer serving as Chief Medical Officer, was granted 289,000 Phantom Units on 09/04/2025. Each Phantom Unit equals one share of common stock and the award was granted at $0 per unit. The Phantom Units vest in 12 equal quarterly installments beginning November 5, 2025, contingent on continuous service, and vested units are payable solely in cash based on the fair market value of the underlying shares upon specified settlement events including termination by the issuer without Cause, a liquidity change in control, or the seventh anniversary of the grant. The filing reports 289,000 shares beneficially owned following the transaction and is signed by an attorney-in-fact on 09/05/2025.
Emil Chuang, a director of Palisade Bio, Inc. (PALI), was granted 18,800 phantom units on 09/04/2025. Each phantom unit equals one share of common stock and the units were granted at $0 per unit. The units vest in three equal annual installments beginning August 5, 2026, subject to continued service.
Vested phantom units will be settled solely in cash based on the fair market value of the equivalent number of shares upon termination of service, a defined liquidity change in control, or the seventh anniversary of the grant. The Form 4 reports 18,800 shares beneficially owned following the transaction and is signed by attorney-in-fact Ryker Willie on 09/05/2025.
Fragment from Palisade Bio, Inc.'s definitive proxy (DEF 14A) lists beneficial ownership counts for named individuals. The excerpt shows Donald Williams with 7,178 shares, Binxian Wei with 4,115 shares, J.D. Finley with 34,351 shares, Mitchell Jones, M.D., Ph.D., with 13,307 shares, and a total line showing 58,951 (context truncated). The table fragment also indicates that an asterisk denotes holdings that represent less than one percent. Several entries (Emil Chuang and others) show a dash or are otherwise not quantified in this excerpt. This content is a partial ownership table and does not provide broader narrative, percentages relative to outstanding shares, or transaction details.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 478,945 shares of Palisade Bio, Inc. The filing states the Reporting Persons share voting and dispositive power over these shares, representing 4.99% of the outstanding common stock. Armistice Capital is disclosed as the investment manager of the direct holder, the Master Fund, and Steven Boyd is identified as the managing member of Armistice Capital. The Master Fund is described as the direct holder but disclaims beneficial ownership due to its investment management agreement with Armistice Capital. The filing affirms the holdings were acquired in the ordinary course of business and not for the purpose of changing control.
FAQ
What is the current stock price of Palisade Bio (PALI)?
What is the market cap of Palisade Bio (PALI)?
